Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial
Halme, A. L. E.; Laakkonen, S.; Rutanen, J.; Nevalainen, O. P. O.; Sinisalo, M.; Horstia, S.; Mustonen, J. M. J.; Pourjamal, N.; Vanhanen, A.; Solidarity Finland Investigators, ; Rosberg, T.; Renner, A.; Perola, M.; Paukkeri, E.-L.; Patovirta, R.-L.; Parkkila, S.; Paajanen, J.; Nykanen, T.; Mantyla, J.; Myllarniemi, M.; Mattila, T.; Leinonen, M.; Kulmasu, A.; Kuutti, P.; Kuitunen, I.; Kreivi, H.-R.; Kilpelainen, T. P.; Kauma, H.; Kalliala, I. E. J.; Jarvinen, P.; Hankkio, R.; Hammaren, T.; Feuth, T.; Ansakorpi, H.; Ala-Karvia, R.; Guyatt, G. H.; Tikkinen, K. A. O.
Show abstract
We report the short- and long-term results of the SOLIDARITY Finland on mortality and other patient-important outcomes in patients hospitalised for COVID-19. Between 08/2021 and 03/2023, we randomised 156 patients in 15 hospitals. In the imatinib group, 7.2% of patients had died at 30 days and 13.3% at 1 year and in the standard of care group 4.1% and 8.3% (adjusted HR at 30 days 1.09, 95% CI 0.23-5.07). In a meta-analysis of randomised trials of imatinib versus standard of care (n=732), allocation to imatinib was associated with a mortality risk ratio of 0.73 (95% CI 0.32-1.63). At 1-year, self-reported recovery occurred in 79.0% in imatinib and in 88.3% in standard of care (RR 0.91, 95% CI 0.78-1.06). Of the 21 potential long COVID symptoms, patients often reported moderate or major bother from fatigue (24%), sleeping problems (19%) and memory difficulties (17%). We found no convincing difference between imatinib and standard of care groups in quality of life or symptom outcomes. The evidence raises serious doubts regarding the benefit of imatinib in reducing mortality, improving recovery, and preventing potential long COVID symptoms when given to patients hospitalised for COVID-19.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.